The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers
Table 13
Percentage of DC subsets and expression of costimulatory and LNH molecules in the circulation of women with LLABCs.
mDC1s and pDCs
% of subsets and costimulatory molecules in women with LLABCs ()
% of subsets and costimulatory molecules in HFDs ()
value
Lin1−, HLA-DR+ DCs
1.26 ± 0.20
1.70 ± 0.30
0.034
mDC1high (Lin1−, HLA- DR+, CD11c+CD1c+)
0.10 ± 0.04
0.15 ± 0.05
0.045
pDChigh (Lin1−, HLA-DR+, CD11c+CD303+)
0.03 ± 0.02
0.06 ± 0.02
0.041
mDC1 HLA-DR+
47.30 ± 8.00
65.00 ± 3.10
0.045
pDC HLA-DR+
48.12 ± 9.50
65.52 ± 5.00
0.002
mDC1 CD40+
35.01 ± 8.00
44.87 ± 6.50
0.011
mDC1 CD80+
1.40 ± 0.60
1.87 ± 0.35
NS
mDC1 CD83+
3.18 ± 0.40
4.04 ± 0.30
0.047
mDC1 CD86+
28.56 ± 3.00
34.07 ± 8.00
NS
mDC1 CD197+
20.35 ± 4.50
24.68 ± 9.00
NS
LNH: lymph node homing; LLABCs: large and locally advanced breast cancers; mDC1: myeloid dendritic cell; pDC: plasmacytoid dendritic cell; HFDs: healthy female donors; NS: nonsignificant; statistically significant.
